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Abstract
Despite the availability of efficacious treatments, only half of patients with hypertension achieve 
adequate blood pressure (BP) control. This paper describes the protocol and baseline subject 
characteristics of a 2-arm, 18-month randomized clinical trial of titrated disease management 
(TDM) for patients with pharmaceutically-treated hypertension for whom systolic blood pressure 
(SBP) is not controlled (≥140mmHg for non-diabetic or ≥130mmHg for diabetic patients). The 
trial is being conducted among patients of four clinic locations associated with a Veterans Affairs 
Medical Center. An intervention arm has a TDM strategy in which patients' hypertension control 
at baseline, 6, and 12 months determines the resource intensity of disease management. Intensity 
levels include: a low-intensity strategy utilizing a licensed practical nurse to provide bi-monthly, 
non-tailored behavioral support calls to patients whose SBP comes under control; medium-
intensity strategy utilizing a registered nurse to provide monthly tailored behavioral support 
telephone calls plus home BP monitoring; and high-intensity strategy utilizing a pharmacist to 
provide monthly tailored behavioral support telephone calls, home BP monitoring, and 
pharmacist-directed medication management. Control arm patients receive the low-intensity 
strategy regardless of BP control. The primary outcome is SBP. There are 385 randomized (192 
intervention; 193 control) veterans that are predominately older (mean age 63.5 years) men 
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(92.5%). 61.8% are African American, and the mean baseline SBP for all subjects is 143.6mmHg. 
This trial will determine if a disease management program that is titrated by matching the intensity 
of resources to patients' BP control leads to superior outcomes compared to a low-intensity 
management strategy.
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1. Introduction
Despite its prevalence, associated morbidity and mortality, presence of evidence-based 
guidelines, and availability of more than 100 anti-hypertensive medications,1 only 
approximately half of American adults with hypertension (HTN) have achieved adequate 
blood pressure (BP) control.2, 3 Clinical trial results indicate that self-management support is 
critical to successful management of HTN and other chronic conditions.4–8 Results from 
randomized trials would typically lead decision-makers to implement effective strategies per 
protocol. However, one size may not fit all. Instead, analogous to titrating medications when 
BP is above clinical targets,9 patients might reasonably require differing intensity of disease 
management depending on whether they have achieved these clinical targets. We are 
conducting a pragmatic clinical trial to evaluate the effectiveness of titrated disease 
management in which the intensity of disease management is adjusted based on an 
individual’s systolic blood pressure (SBP).
1.1. Defining Titrated Disease Management (TDM)
We view the process of TDM as analogous to the common process of titrating medication 
dosage in clinical care. For example, clinical guidelines often recommend adjusting the 
dosage and/or number of anti-hypertensive agents based on clinical parameters. This is often 
in the form of stepped care, where patient’s initial medication dose is low to minimize risks 
of treatment (such as side effects).10 If patients are not responsive to initial treatments, their 
medication regimen is intensified until clinical goals are met. Absent some change in the 
underlying pathophysiology of disease (e.g., weight loss) or side effects, patients do not have 
their treatment reduced once clinical goals are reached; it is assumed that any reduction in 
intensity would diminish level of control.11–13
We are conducting a pragmatic trial to examine the effectiveness of titrated (not stepped) 
care when applied to disease management. Specifically, we are adjusting (titrating) the 
resource intensity (and expense) of a disease management strategy based upon the patient’s 
clinical status. Depending on the individual’s BP, resources are either intensified or reduced 
to achieve or maintain BP control. This resource intensity differs by: 1) who delivers disease 
management; 2) the complexity of the treatment (i.e., whether there is medication 
intensification); and 3) frequency of patient contacts. The assumption of this novel approach 
is that patients will be titrated to different initial resource levels and will be evaluated over 
time to determine if they will: 1) remain at the same level of resource intensity; 2) increase 
to a higher intensity level; or 3) decrease to a lower resource intensity level. This type of 
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titration addresses a criticism about stepped care where there is no plan to reduce level of 
drug or other resource use for patients with improving illness severity.14
2. Materials and Methods
2.1. Study Sponsorship and IRB Approval
This trial is funded by the United States Department of Veterans Affairs (VA) Health 
Services Research and Development Service (grant # IIR 10–383; clinicaltrials.gov 
registration # NCT01390272). It is being conducted under the approval of the Intuitional 
Review Board (IRB) of the Durham VA Medical Center.
2.2. Specific Aims of the Pragmatic Trial
The primary question of the pragmatic trial is: will the TDM intervention reduce systolic 
blood pressure (SBP) over 18-months compared to licensed practical nurse (LPN)-delivered 
behavioral support calls occurring every two months [control arm]? The primary hypothesis 
is that veterans randomized to TDM will have greater improvement in mean SBP over the 18 
months of follow-up than veterans in the control arm. Secondary outcomes include HTN 
control (dichotomous), cost-effectiveness (if successful), and adherence to hypertension 
medications.
2.2. Setting
The study is being conducted among patients receiving primary care at clinics in four 
separate locations affiliated with the Durham VA Medical Center. One location is the main 
VA hospital, one satellite clinic is located approximately 1.5 driving miles to the north, a 
second clinic is located approximately 45 driving miles to the east, and a final clinic is 
located approximately 110 driving miles east of the hospital. In 2015, these sites had 
approximately 46 primary care provider (PCP) full-time equivalents for delivery of care to 
approximately 44,000 unique patients.
2.3. Summary of the Intervention
This is a two-arm 18-month pragmatic randomized clinical trial for veterans with 
pharmaceutically-treated hypertension and uncontrolled SBP (defined as ≥ 140mmHg for 
non-diabetic or ≥ 130mmHg for diabetic patients). The intervention arm includes three 
levels of resource intensity targeted to improve patients’ SBP (Table 1).
• Low resource intensity: An LPN provides non-tailored behavioral support 
telephone calls every two months to patients whose SBP comes under 
control. The low resource intensity also serves as the control arm 
(described below).
• Medium resource intensity: A registered nurse (RN) provides monthly 
tailored behavioral support telephone calls plus home BP monitoring.
• High resource intensity: A pharmacist provides monthly tailored 
behavioral support telephone calls, home BP monitoring and pharmacist-
directed medication management.
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At the initial baseline visit patients who are randomized into the intervention arm are first 
titrated to either RN or pharmacist levels based on baseline blood pressure values. 
Subsequent titrations that include the LPN level happen at the 6 and 12 month study visits.
In the control arm (Table 1), a LPN provides behavioral support telephone calls every two 
months. This is identical to the low resource intensity component of the TDM intervention. 
This control arm differs from usual care in that patients receive additional regular contact 
that has been shown to enhance BP control among veterans15 and medication adherence 
among North Carolina Medicaid beneficiaries.16
2.4. Eligibility Criteria
Eligible individuals included English speaking adults living in the community with access to 
a telephone who had been seen at a study clinic in the last year, had a VA PCP (Table 2). and 
had a history of pharmaceutically-treated HTN with uncontrolled SBP in the past year.17 
Specifically, based on the Seventh Report of the Joint National Commission on Prevention, 
Detection, Evaluation and Treatment of High Blood Pressure (JNC7), HTN is considered 
uncontrolled if SBP is ≥ 140mmHg for patients without diabetes or ≥ 130mmHg for patients 
with diabetes. While JNC 8 guidelines were issued during the trial,9 we continued to utilize 
JNC 7 criteria so we could maintain consistent therapeutic goals throughout the study. BP 
control was based on mean SBP during the year prior to periodic data pulls from the VA 
electronic health record (described below). Because of the labile nature of blood pressure, 
patients were identified in the data pulls as being potentially eligible based on a SBP 
10mmHG over JNC7 guidelines. (i.e., 150mmHg for patients without diabetes or 140mmHg 
for patients with diabetes).
Patients were excluded if they had known type 1 diabetes, class IV congestive heart failure, 
end stage renal disease, metastatic cancer, a history of solid organ or bone marrow 
transplantation, or a diagnosis of active psychosis at baseline. Additionally, patients were 
excluded if they were enrolled in any ongoing clinical trial or specific clinical program that 
would be expected to impact blood pressure control. Women who reported being pregnant or 
planning to become pregnant over the next 18 months were also excluded.
2.4.1. Change In Inclusion Criteria During the Study—To be eligible, patients were 
initially required to have uncontrolled study SBP (≥ 140mmHg without diabetes; ≥ 
130mmHg with diabetes) at baseline, which was assessed after the patient provided 
informed consent, but before randomization. While this criterion was in place, 41.3% of 
patients who consented did not meet the threshold for being out of control. Because these 
patients are likely to have been cycling in and out of control, we decided patients meeting 
study criteria while having baseline SBP control would likely benefit from the intervention 
and, as such, should be randomized. The IRB approved this modification.
2.5. Screening and Enrollment
Potential subjects were initially identified based upon data extracted from the VA electronic 
health record (EHR) using inclusion and exclusion criteria (above). PCPs were informed of 
the study and could request to review lists of potentially eligible patients to approve patients’ 
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potential participation in the study (i.e., whether individual patients could remain on the list). 
Providers choosing to review lists of potentially eligible patients had 14 days from receiving 
the list to conduct the review and contact study team with any concerns about individual 
listed patients participating in the study. Only one PCP chose to review patient lists.
Letters were sent from the principal investigator and study physician to potentially eligible 
patients allowing them to opt out of the study. For subjects who did not opt-out, study staff 
conducted a screening phone call to further assess inclusion and exclusion criteria and 
schedule baseline study visits. Given the large number of potentially eligible subjects, chart 
review was prioritized for patients having upcoming appointments within 4–6 weeks; doing 
so allowed baseline study visits to coincide with a patient’s clinic visit. After approximately 
7 months of enrollment, patients living within approximately 50 miles of a participating 
clinic were also prioritized to enhance enrollment rates.
2.6. Patient Compensation
Patients receive $15 for each of the four data collection visits (baseline, 6, 12, and 18-
months), for a total potential payment of $60 for participating in the study.
2.7. Protocol for Measuring Baseline and Outcome Systolic Blood Pressure (SBP)
At each study visit (including baseline), the SBP outcome is based on the mean of three BP 
measures obtained 30 seconds apart after the patient has sat for 5 minutes. All BP 
measurements are performed using electronic BP cuffs, which have been shown to be 
equivalent to (and ecologically safer) than the gold standard of random zero 
sphygmomanometers.18 The same type of electronic BP cuff is being used for all clinic 
locations in the study (Omron Digital Blood Pressure Monitor HEM-907XL).
2.8. Randomization
We used blocked randomization stratified by diabetes status (because of differing HTN 
treatment goals) and baseline SBP [up to moderately out of control: SBP < 150mmHg for 
non-diabetic patients (or < 140mmHg for diabetic patients); significantly out of control: SBP 
≥ 150mmHg for non-diabetic patients (or ≥ 140mmHg for diabetic patients)]. Research 
assistants were blinded to randomization block size. Diabetes was defined from EHR data as 
having both: ICD-9 diagnosis code 250.xx on ≥ 2 outpatient encounters during the prior year 
and a prescription for oral hypoglycemic medication (e.g., sulfonylurea, metformin, 
thiazolidinedione, secretagogues, acarbose) and/or insulin during the past year.
It was not feasible to blind personnel who collected study outcome data to the assigned 
study arm. To minimize bias, baseline outcome data were collected prior to randomization 
and SBP measurement outcome data collection utilized an electronic blood pressure 
machine and standard protocol, which is described above.
2.9. Intervention
2.9.1. Titration Algorithms—The protocol for titrating resource intensity of the 
intervention depended on BP control. Titration algorithms are detailed in Table 3.
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2.9.2. Intervention Component – Telephone Self-Management Support 
[medium- and high-level resource intensity]—Patients receiving medium resource 
intensity disease management receive calls from a RN; patients receiving high resource 
intensity disease management receive calls from a pharmacist (PharmD). The calls combine 
tailored information and feedback that address aspects of hypertension management 
specifically relevant to a particular patient.19 Drawing on stages of change,20, 21 and a 
revised Health Decision Model (HDM) that considers how patients’ beliefs, environment, 
and characteristics impact decisions concerning health behaviors,21–23 the intervention 
addresses how to: 1) set realistic, healthy goals that reflect patient preferences and readiness 
to change and support self-efficacy for achieving those goals,24–27 2) implement healthful 
behaviors and monitor performance, and 3) maintain the behaviors and associated 
hypertension control over time. To further tailor the intervention, callers use scripted 
modules based on patients’ specific needs identified from questions asked during the call. 
For example, patients who report they are current smokers are asked about their readiness to 
quit smoking.
Training Personnel Making Calls: Prior to starting the intervention, the RNs and 
pharmacist delivering the calls were trained in motivational interviewing (MI). MI is a tool 
that can assist individuals work through ambivalence about behavior change. Interventionists 
were provided didactic training on the basic principles of MI, including asking open-ended 
questions, learning how to use reflective listening, and learning to identify and elicit “change 
talk” from a patient. The LPN delivering low resource intensity calls did not receive training 
in MI and followed non-tailored telephone call scripts.
Mechanics of Making Calls: The interventionist calls patients within two weeks after 
randomization. Subsequent contacts are scheduled approximately monthly. Between 
scheduled calls, patients are encouraged to telephone the interventionist with questions 
related to their hypertension, including (but not limited to) control of their BP and the 
pharmacological or non-pharmacological management of HTN. Should emergent healthcare 
issues arise during these calls, the study contacts the patient’s PCP (or covering provider) via 
a note in the EHR or refers the patient to emergency care.
Content of Calls: The interventionist utilizes computerized software to guide tailored 
patient modules during the intervention calls. Each module addresses either (1) a health 
behavior (e.g., exercise) that is desirable for BP control or (2) a modifiable patient factor that 
can improve control (e.g., hypertension knowledge, memory) that may impact medication 
adherence. The modules are “activated” (introduced as a topic) when a patient reports a 
barrier that the module was designed to address.
A major emphasis of the intervention is initiating and maintaining specific health behaviors 
related to HTN. During each monthly call, a core group of modules were available. All RN 
and PharmD phone calls addressed medication management, side effects (with the exception 
of the first call) and home BP monitoring. An additional health behavior or modifiable 
patient factor was also addressed. Topics covered in calls can be found in Table 4. The call 
schedules for the RN, pharmacist, and LPN (control arm) calls can be found in Table 5.
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2.9.3. Intervention Component – Booster Level Phone Calls—Patients whose SBP 
comes under control at 6 or 12 months are switched to low resource intensity LPN phone 
calls. Low resource intensity calls occur every two months instead of monthly and follow a 
standardized script with no tailoring or probing about BP measurements.
2.9.4 Intervention Component – Home BP Monitoring: Medium and High 
Resource Intensity—All patients randomized to the intervention arm who do not 
currently have a VA approved home BP monitor were eligible to receive one. They receive 
training in its use at their baseline study visit according to a protocol developed in our prior 
studies.28 Patients are instructed to check their BP every other day using a defined protocol 
similar to previous studies.29 We request individuals to provide their BP values for the two 
weeks prior to the monthly intervention calls so that the interventionist (RN or pharmacist) 
could assess their BP control. Patients are reminded to record their BP as part of the 
intervention calls.
2.9.5. Intervention Component – Pharmacist-Directed Algorithmic Medication 
Management [high resource intensity only]—Patients who meet criteria for high 
resource intensity disease management receive medication management from a clinical 
pharmacist, who will be backed up by a study physician. Pharmacists are authorized to make 
medication changes according to accepted treatment algorithms and based on their scope of 
practice. Via the VA EHR, the pharmacist will also communicate these changes to the 
patient’s PCP. While pharmacists in the VA may collaborate with the patients’ providers 
when clinically indicated, they do not have to rely on them to make the changes. The study 
pharmacist attempts to contact patients every month while they are in the high-intensity 
titration level of the intervention. During each contact, the pharmacist has information from 
both the VA EHR and the behavioral support calls conducted as part of the intervention so 
information on such topics as patient medication and barriers to adherence can be available. 
During the initial call, the pharmacist assesses the patient’s medication adherence, reviews 
all BP-related medications, and discusses the purpose and appropriate administration of each 
medication. The pharmacist (or appropriately licensed clinical backup) may discuss other 
medicines if he or she feels that this is needed to appropriately manage BP medication. At 
subsequent contacts, the pharmacist reviews any medication changes with the patients and 
updates patients’ medication lists. For patients who require a change in their prescription, 
the pharmacist writes the prescription, and then communicates the change to the patient’s 
PCP using standard clinic procedures.
2.10. Control Arm
Control patients receive the low resource intensity intervention, which is described above, 
for the entire study period.
2.11. Outcomes and Study Measures
Table 6 lists all study measures and time points at which information is being collected.
2.11.1. Primary Outcome – Continuous Change in Systolic Blood Pressure—
SBP is the primary outcome because it has greater association with cardiovascular disease 
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risk than diastolic BP among patients with pharmaceutically-treated hypertension.30–32 The 
procedure for measuring SBP at all study visits is described above in section 2.7.
2.11.2. Secondary Outcome – SBP Control—This is a dichotomous outcome in 
which control is defined as SBP ≤ 130mmHg for hypertensive patients with diabetes and ≤ 
140mmHg for patients without diabetes.
2.11.3. Secondary Outcome – Adherence to Blood Pressure Medication—
Adherence is measured as the supply of medications patients have, expressed as a 
Medication Possession Ratio (MPR). We use the ReComp MPR algorithm,33, 34 which was 
developed and validated using pharmacy refill data to measure adherence with 
antihypertensive medication [considered together for adherence].
2.12. Planned Data Analysis
Our pre-specified primary and secondary hypotheses will be tested with two-sided p-values 
at the p < 0.05 level using intent-to-treat basis; we analyze all data up to the 18-months 
follow-up (or last available prior to exclusion or dropout).35 Statistical analyses will be 
performed using SAS for Windows (version 9.4: SAS Institute, Cary, NC) and R (http://
www.R-project.org).
2.12.1. Planned Analysis—To examine the impact of TDM on mean SBP over 18 
months, we will use a linear mixed model.36 Baseline, 6-, 12- and 18-month values in the 
response vector will be used to estimate changes in SBP over time and test the primary 
hypothesis. The predictors in the model will include time and the intervention-by-time 
interaction. This constrained longitudinal model (cLDA) assumes the study arms have equal 
baseline means, which is appropriate for a randomized control trial and is equivalent in 
efficiency to an ANCOVA.37 Results from exploratory graphical methods as well as model 
selection criteria will be used to select the most appropriate way to model time over the 18 
month follow up.
We will fit models using the SAS procedure MIXED (Cary, NC), which handles dropout in a 
principled manner. However, depending on the type and scope of missing data, we will also 
explore multiple imputation as a strategy to use in conjunction with our primary analytic 
tools.38 Secondary analyses will be conducted in a similar manner, testing for differences in 
medication adherence as a continuous outcome. For BP control and dichotomous adherence, 
similar modeling procedures will be followed using generalized linear mixed models using 
PROC GLIMMIX with adaptive quadrature.36
2.12.2. Sample Size Considerations—We estimated that 400 subjects (200 per arm) 
would be required to detect a 5mmHg difference in SBP at 18 months with 80% power and a 
type-I error of 5%. We used a method based on ANCOVA type analyses39 where we 
assumed an expected mean baseline mean SBP of 145mmHg, standard deviation of 
17.5mmHg, correlation between repeated measurements of 0.4, and attrition rate of 15% by 
18 months.
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2.12.3. Planned Analysis of Secondary Outcome – Cost Effectiveness—The 
primary objective of the cost-effectiveness analysis is to estimate the cost per unit difference 
in effectiveness (if intervention is effective). The incremental cost effectiveness ratio (ICER) 
will be calculated as the difference in the average cost per patient between the treatment and 
control arm divided by the difference in mmHg between the treatment and control arms. 
Salaries specific to LPN, RN, and pharmacist will be used to calculate cost of interventionist 
time. This time includes preparing for intervention calls, attempting to make calls, and 
delivering the intervention. We will account for the amount of time that patients spend at the 
high, medium, and low resource levels of the intervention (including actions taken). 
Sensitivity analyses will also be performed on types of costs: intervention, resource 
utilization, and total (intervention plus resource utilization) costs. If there are no differences 
in resource utilization across arms, we will simply include the intervention costs in the ICER 
calculation. All dollars will be expressed in constant dollars (e.g. 2016), using the Consumer 
Price Index for Medical Care for medical items or Consumer Price Index for other items.
3.0. Results of Enrollment Procedures
Chart review eligibility assessments were performed on 5,812 patients (Figure 1). Patients 
may have been found to be ineligible during the recruitment process (2,185), not prioritized 
for further screening based on operating procedures described above (1,246), unable to 
contact for or fully complete a recruitment process [e.g., not able to complete a screening 
call in the time allotted] (605), not attending the baseline study visit (123) or have declined 
to participate when the recruitment letter was sent, during the screening telephone call, or at 
the baseline/consent study visit (1,268). In total, 385 veterans were enrolled and randomized 
between November 6, 2012 and April 9, 2015, 192 to the intervention arm and 193 to the 
control arm.
Reflecting the VA patient population as a whole, subjects are predominately men (92.5%). 
Their mean age was = 63.5 years. The majority of patients are black (61.8%), with 33.8% 
being white and 4.5% being of another race or multiple races; 3.4% are of Latino(a) or 
Hispanic origin or decent. The majority are married (57.0%) and approximately one-quarter 
have a low level of literacy. More than half have diabetes (57.1%) and mean baseline SBP of 
143.6mmHg). Detailed baseline characteristics by arm can be found in Table 7. The two 
arms were similar at baseline.
4.0. Discussion
The TDM Trial is a pragmatic trial designed to test interventions in “real world” practices so 
that, if effective, they can be more rapidly implemented. In this particular study intervention 
patients have the intensity of their care titrated based upon their BP control.40–42 By 
reserving the most intensive and expensive strategies to veterans with greatest clinical need, 
this titrated strategy can potentially lead to more efficient use of resources. Our study of how 
to best and most efficiently allocate disease management resources will provide critical 
evidence about increasing access to enhanced primary care required under the VA patient-
aligned care team (PACT) model, the VA’s version of the Patient Centered Medical Home 
(PCMH).43–45 Further, the study will provide evidence concerning whether the titrated 
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disease management process may be used as a method for healthcare systems to enhance the 
allocation of scarce resources.
The TDM Trial recognizes that LPNs, RNs, and clinical pharmacists have varying scopes of 
practice, as well as differing salaries. LPNs [known as licensed vocational nurses (LVNs) in 
California and Texas] differ from RNs in several important dimensions. While both are 
nurses, LPNs focus on providing specified services under the direction of another licensed 
clinician, often a RN. While RNs can assess patients and develop plans for nursing care, 
LPNs cannot independently assess and take action in relation to patient care. As we have 
done, LPNs complete assigned patient care tasks, observe patients, and report observations 
to other clinicians. Further, RNs have training in areas such as educating patients about 
health issues. As a result of their greater responsibilities and time in training, RNs are paid 
significantly more than LPNs.46, 47
Clinical pharmacists have been studied as part of clinical teams managing hypertension to 
improve BP control.7, 48 They are trained in medication management and, in that role, can 
provide clinical assessments of patients. In the VA and many states, clinical pharmacists can 
directly prescribe medications within their scope of practice. Even in settings where 
prescribing is not permitted pharmacists can recommend pharmaceutical management to 
prescribing providers. However, there are far fewer clinical pharmacists than nurses 
available to participate in disease and self-management programs in most clinical settings, 
making use or RNs and LPNs appealing, when clinically appropriate. Additionally, clinical 
pharmacists have significantly higher salaries due to their greater scope of practice.
The TDM Trial is testing a disease management program that 1) matches the resources 
intensity and skill set of clinicians to the clinical needs of patients and 2) allows the intensity 
to be adjusted up or down over the course of the program. The strategy is appealing because 
most health systems do not have the human resources necessary to provide the highest 
intensity resources to all patients who could potentially benefit from disease management 
programs and patients’ clinical needs likely vary over time. Finally, the decision was made 
to test the intervention against a type of non-tailored telephone intervention that has been 
previously shown to improve blood pressure control because we believed that organizations 
would need to see superiority over such a low intensity program to consider the potential for 
utilizing resources to implement a TDM approach.
The TDM Trial has limitations and considerations that may impact the study. The 
participants are predominantly older men, which reflects the VA population as a whole.49 
Further, the trial is being conducted among patients receiving primary care from one of four 
locations affiliated with only one VA medical center. Although our participants are racially 
diverse and are socioeconomically vulnerable, these factors limit generalizability. Second, 
we did not have the study personnel needed to maintain blinding among those collecting 
study outcomes. However, baseline outcomes were obtained before randomization, and we 
used a standardized protocol for measuring BP and implemented procedures to audit and 
maintain data quality. These processes have been employed to reduce the potential of bias 
resulting from the inability to maintain blinding during the study. Third, we lack the 
resources to examine whether any differences in results will continue after the study ends. 
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However, we recently evaluated clinical benefits of calls similar to those in the TDM Trial 
and home BP monitoring after the trial concluded. The positive effect of the intervention, 
which did not include titration of resource intensity, was sustained 18 months following 
study conclusion50 Finally, we were not able to maintain our original goal of only including 
patients who had uncontrolled SBP at baseline. In the final sample, 23.4% of patients had 
blood pressure under control based on measurements collected at the baseline study visit.
5.0. Conclusion
The TDM Trial is a pragmatic health services research clinical trial testing an 18-month 
intervention titrating the resource intensity of disease management based on the clinical 
status of patients. The 385 individuals randomized in the trial represent a diverse group of 
veterans treated by the VA. The VA, like all healthcare organizations, must make the best use 
of available resources to enhance the health of those who receive care within the system. The 
TDM Trial will provide additional evidence concerning how to organize population-health 
interventions to lead to maximum benefit of patients.
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Figure 1. 
Study Flow through Randomization
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Table 1
Summary of Differences in Intervention Resource Levels
Attributes Resource Level
Low* Medium High
Delivered by Licensed Practical Nurse
(LPN)
Registered Nurse (RN) Pharmacist
Key clinician attributes • Able to 
follow 
directions 
of higher 
level 
clinicians 
per 
protocol
• May not do 
clinical 
assessments
• Can use 
clinical 
judgment to 
answer 
clinical 
questions 
and provide 
related 
assistance 
to patients
• Can do 
clinical 
nursing 
assessments
• Can 
prescribe 
medication
• Trained in 
medication 
management
• Can provide 
clinical 
assessments 
of patients
Behavioral call frequency Every two months Monthly Monthly
Modules activated by
telephone calls will be
tailored to patient
No Yes Yes
Clinician trained in
motivational 
interviewing
No Yes Yes
Home BP monitoring Not part of intervention Yes Yes
Pharmaceutical
management
No No Yes
*
The control arm for the study is delivery of the LPN / low intensity calls as described.
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Table 2
Inclusion and Exclusion Criteria
Inclusion Criteria
Inclusion Criteria Determined by Initial Review of the VA Electronic Health Record
• Age ≥ 18 years
• Assigned PCP in one of the clinics of the Durham VAMC (including CBOCs).
• Had at least 1 primary care visit at the Durham VA or affiliated clinics in the last year.
• Diagnosis of hypertension requiring medication, as determined by:
➢ International Classification of Disease Ninth Revision (ICD-9) 401.0, 401.1, or 401.9 for ≥ 2 outpatient 
encounters during the prior year and
➢ Received a prescription for at least 1 of the following classes of hypertensive medication in the previous 
year: 1) ACE inhibitors; 2) alpha blockers; 3) angiogenesis II inhibitors; 4) beta blockers; 5) calcium 
channel blockers; 6) diuretics; 7) antihypertensive combination; and/or 8) antihypertensives, other
• Out of control systolic blood pressure: Durham VAMC (including CBOCs or other affiliated clinics captured in the 
Durham VAMC electronic health record) outpatient BP measurements ≥ 150mmHg for non-diabetic or ≥ 140mmHg for 
diabetic patients over the last year. If additional patients need to be approached to be offered the opportunity for further 
screening, non-diabetic patients with mean outpatient systolic BP of ≥ 140mmHg or diabetic patients with mean 
outpatient systolic BP of ≥ 130mmHg over the past year may be approached. Systolic BP cutoffs are based on the 
Seventh Report of the Joint National Commission on Prevention, Detection, Evaluation and Treatment of High Blood 
Pressure (JNC 7).17 Initial screening BP levels were inflated because of evidence that patients frequently have lower 
study baseline BPs than would be expected based on the mean of clinic BP results over the last year.51
Inclusion Criteria Determined during the Initial Screening Phone Call
• Has a VA or affiliated clinic provider that they consider to be their main PCP.
• Receives the majority of healthcare at the Durham VAMC (or affiliated clinic).
Exclusion Criteria
Exclusion Criteria Determined by Initial Review of the VA Electronic Health Record by Chart Review
• Active diagnosis of psychosis.
• Diagnosis of metastatic cancer.
• Type 1 diabetes
• Class IV congestive heart failure (CHF).
• Currently receiving kidney dialysis or if estimated glomerular filtration rate (eGFR) levels are ≤ 15.
• Former, current or pending solid organ or bone marrow transplant patient.
• Chronic obstructive pulmonary disease (COPD) requiring oxygen.
• Resident in nursing home or receiving home healthcare.
• Patient is pregnant.
• At the time of potential enrollment, participating in another ongoing hypertension, diabetes, cholesterol, or 
cardiovascular disease (CVD) clinical trial or patient-level hypertension and/or CVD related quality improvement 
management program that the study investigators consider likely to be a co-intervention.
Exclusion Criteria Determined during the Initial Screening Phone Call
• Refusal or inability to consent to an in-person baseline visit.
• Planning to leave the area prior to the anticipated end of participation.
• Inability or unwillingness to come to the Durham VAMC for baseline-, 6-, 12-, and 18-month study visits
• Does not have reasonable access to a telephone.
• Does not speak English.
• Resident in nursing home or receiving home healthcare.
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• Severely impaired hearing or speech (Patients must be able to respond to phone calls.)
• Severely impaired vision (Patients must be able to read mailed material).
• At the time of potential enrollment, participating in another ongoing hypertension, diabetes, cholesterol, or 
cardiovascular disease clinical trial.
• Patient reports currently receiving dialysis (may or may not be at the VA).
• Type 1 diabetes, as reported by the patient.
• Patient indicates she is pregnant or planning to become pregnant in the next two years.
• Patients with class IV CHF, dialysis-requiring renal disease, and type 1 diabetes have blood pressure and/or blood sugar 
management that are beyond the scope of a primary care pharmacist. Exclusion of patients with COPD requiring 
oxygen and class IV CHF is done (similar to our exclusion of patients with metastatic cancer) to keep patients with end-
stage or near end-stage illness out of the study, both because their life expectancies minimize the importance of 
hypertension control.
Exclusion Criteria Determined during the Baseline In-Person Visit
• Refusal or inability to provide informed consent and HIPAA authorization form.
• Arm size > 50 cm in circumference
• Unable to obtain (including by arm) valid blood pressure readings
• Inadequate mental status to complete the protocol, as judged by five or more errors on the Short Portable Mental Status 
Questionnaire (SPMSQ).52–54
• Patients who report that they are pregnant or have the potential to become pregnant during the study.
BP - blood pressure; CBOC - community-based outpatient clinic; CVD - cardiovascular disease; PCP - primary care provider; VAMC - Veterans 
Affairs Medical Center
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Table 3
Intervention Titration Algorithm
Baseline Titration
Based on mean baseline study visit SBP values:
• Medium resource intensity – Monthly tailored RN delivered calls + home BP monitoring
➢ Mean of enrollment study visit SBPs of < 150mmHg (< 140mmHg for patients with diabetes)
• High resource intensity – Monthly tailored pharmacist delivered calls with additional medication management + home 
BP monitoring
➢ Mean of enrollment study visit SBPs of ≥ 150mmHg (≥ 140mmHg for patients with diabetes)
Planned Titration at 6 and 12 Months
Based on the mean of all available SBP values up to 31 days prior to the patients study visit, including study visit BP values, any clinic BP 
values, and/or any home BP values provided to during the intervention:
• Low resource intensity – Non-tailored LPN delivered calls occurring every two months
➢ Mean SBP controlled; i.e. <140mmHg (SBP <130mmHg for patients with diabetes).
• Medium resource Intensity
➢ Mean SBP (defined above) of ≥ 140mmHg and < 150mmHg (≥ 130mmHg and < 140mmHg for patients 
with diabetes)
• High resource Intensity
➢ Mean SBP (defined above) of ≥ 150mmHg (SBP ≥ 140mmHg for patients with diabetes)
Unplanned Titration Between 6 and 12 Months
• Mean of home SBPs reported during a study behavioral call ≥ 160mmHg
➢ This automatic increase in resource intensity will not include adding 5mmHg to home systolic BP 
measurements. A minimum of 4 blood pressure readings considered to be validly reported by the 
appropriately licensed clinical interventionist was required. Any exception to the required number would 
need to be approved by the study physician or an appropriately licensed clinical backup.
• Hospitalization due to stroke and/or myocardial infarction. Patient will be asked at intervention phone calls if they have 
been hospitalized for stroke, myocardial infarction and/or heart attack. We will also make unplanned titrations due to 
hospitalizations that are noted by interventionists as having been recorded in the VA electronic health record.
• A patient triggers the safety protocol based on a blood pressure.
If a patient is titrated to the highest level between study visits, they must remain at the highest
intensity level for at least 6 months (for example, if a patient is up stepped at month 3, they will
not be reevaluated for possible down stepping until month 12).
BP - blood pressure; mmHg – millimeters of mercury; LPN – licensed practical nurse; RN – registered nurse; SBP – systolic blood pressure; VA – 
Veterans Affairs
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Table 4
Intervention Arm Module Content – Medium (RN) and High (pharmacist) Resource Levels*
Topic Module Content
Opening
Module/Medication
Management
[delivered during each 
call]
1 Review of currently prescribed BP medication, assessing if the participant is familiar with the 
purpose of the medication, and whether there have been any changes in the use of the their 
hypertensive medications.
2 If the patient does not understand the purpose of their hypertension medication in any 
encounter or how to take the medication, the interventionist explains the purpose of each 
medication prescribed for that individual.
3 If the patient reports that there has been a change in their BP medications, the interventionist 
queries if their PCP is aware of the change. If not, the interventionist discusses the 
importance of informing their PCP of changes in their BP medication regimens.
Adverse Effects of
Antihypertensive
Medication
[delivered during each 
call]
1 Patients are queried at every scheduled phone call about any specific BP medication side 
effects they may have.
2 If a patient is having a hypertension-medication related adverse effect, the interventionist 
discusses the problem with the patient. The interventionist also reminds the patient to discuss 
any adverse effects with their PCP. Any potentially life threatening adverse effect is reported 
immediately to the PCP. The goal is to prevent medication nonadherence by informing 
patients of common adverse effects and help to facilitate medication change when necessary.
Memory 1 Patients who report they have difficulties remembering to take their medication are provided 
various mnemonic strategies such as setting an alarm or using a weekly pillbox.55
2 The interventionist conveys the need and importance of taking BP medication consistently 
and in a timely manner.
Knowledge/Risk
Perception
1 All patients will receive information and counseling from the interventionist on the 
importance of maintaining BP control by underscoring the association between hypertension 
and diseases that come about from poor control. Counseling is tailored to individuals who are 
diabetic,56–58 African American,59, 60 recently diagnosed with hypertension, and/or have 
hypertensive relatives61, 62 because these factors confer specific risks for worse health 
outcomes.
Participatory 
Decision-
Making and Patient-
Provider 
Communication
1 Patients identified as having poor provider relationships receive information on ways to 
empower patients to interact more productively with their providers.
Diet 1 Patients are asked to choose a topic of interest for them for information on low sodium diet, 
healthy carbohydrates, or heart healthy choices and portion control.
2 Patients are also asked to talk about foods they eat in a typical day.
3 There is a discussion of sodium and sources of where high levels of sodium may be found, 
followed by having individuals think of ways they can reduce their sodium intake.
4 The interventionist discusses how individuals can determine the sodium contents of food and 
remind patients of how much sodium they should ingest in a day. This material includes the 
Dietary Approaches to Stop Hypertension (DASH) diet, which has been found to lower 
BP.63–65
Weight 1 The interventionist emphasizes the importance of maintaining a healthy weight and queries 
individuals as to what stage they are in terms of initiating weight loss (not ready, thinking 
about it, preparing, or taking action).
2 Weight loss information is then tailored to individuals’ readiness to change.
Exercise 1 The interventionist reviews the benefits of exercise and assesses current physical activity and 
whether individuals have increased their level of physical activity since enrolling in the study.
2 The interventionist determines their exercise activity readiness to change and information is 
then tailored to the patient’s readiness.
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Topic Module Content
3 The interventionist also helps the individual to determine the intensity level of their planned 
activities as well as setting realistic goals.
Social and Medical
Environment/Access 
to
Care.
1 If barriers to care (e.g., lack of transportation, medical costs, social isolation) are identified, 
the interventionist assists patients in identifying and using available resources to overcome 
barriers (e.g., community resources, inexpensive medications).
Stress, Mental 
Health,
Insomnia and Sleep
Apnea.
1 Patients are asked about their knowledge of the relationship between stress and hypertension 
as well as how individuals know when they are stressed.
2 The interventionist provides some suggestions on how to potentially reduce stress, monitor 
their sleep habits and, if appropriate, be referred to the sleep apnea clinic. Among individuals 
who screen positive on Patient Health Questionnaire (PHQ)-266, 67 [2 item screening 
instrument for depression], the interventionist will discuss various treatments available (e.g., 
medication, therapy), the importance of seeking treatment, and how to access these resources 
as a VA patient.
3 Patients are asked the Berlin Questionnaire (for sleep apnea) during the 6 month study visit to 
identify patients at risk for the sleep apnea syndrome. The questionnaire consists of 3 
categories related to the risk of having sleep apnea. Patients can be classified into High Risk 
or Low Risk based on their responses to the individual items and their overall scores in the 
symptom categories. High Risk patients trigger a module where the interventionist discusses 
the result and encourages participant to discuss a referral for diagnostic polysomnogram 
(PSG) evaluation for sleep apnea with their PCP.
Smoking 1 Among smokers, the interventionist highlights the benefits of smoking cessation for those 
who report they are current smokers.
2 The interventionist then determines the individual’s stage in terms of considering smoking 
cessation.
Closing Module
[delivered during each 
call]
1 The interventionist asks patients to report their most recent blood pressure. If they are not 
aware of it, the interventionist reiterates the importance of knowing one’s blood pressure.
2 For those patients who know their blood pressure, the interventionist provides feedback for 
those with inadequate blood pressure control and further reinforcement for those with 
adequate blood pressure control.
BP - blood pressure; PCP - primary care provider
*
LPN calls provide knowledge-based information on these topics, with the exception of diet, exercise, mental health, and sleep apnea based on the 
schedule in Table 5.
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Table 5
TDM Trial Module Schedule
RN & PharmD Encounters with Module Topic
Encounter 1:
Opening/Closing
Medications/Side Effects
CVD knowledge
Memory
Adverse Events
Encounter 7
Opening/Closing
Medications/Side Effects
Weight loss
Alcohol
Adverse Events
Encounter 13
Opening/Closing
Medications/ Side Effects
Weight loss goal f/u
Adverse Events
Encounter 2
Opening/Closing
Medications/ Side Effects
Tobacco use
Social Support
Adverse Events
Encounter 8
Opening/Closing
Medications/ Side Effects
Diet
Tobacco use goal f/u
1 mo weight loss f/u
Adverse Events
Encounter 14
Opening/Closing
Medications/ Side Effects
Alcohol
Adverse Events
Encounter 3
Opening/Closing
Medications/ Side Effects
Mental Health
1 mo f/u tobacco use
Adverse Events
Encounter 9
Opening/Closing
Medications/ Side Effects
Insomnia
Apnea
Adverse Events
Encounter 15
Opening/Closing
Medications/ Side Effects
Insomnia
Apnea
Adverse Events
Encounter 4
Opening/Closing
Medications/ Side Effects
Diet
Pt-Physician Interaction
Adverse Events
Encounter 10
Opening/Closing
Medications/ Side Effects
CVD knowledge
Memory
Adverse Events
Encounter 16
Opening/Closing
Medications/ Side Effects
Diet
Adverse Events
Encounter 5
Opening/Closing
Medications/ Side Effects
Exercise
Adverse Events
Encounter 11
Opening/Closing
Medications/ Side Effects
Pt-Physician interaction 6 mo f/u
Adverse Events
Encounter 17
Opening/Closing
Medications/ Side Effects
Stress
Adverse Events
Encounter 6
Opening/Closing
Medications/ Side Effects
Stress
1 mo f/u exercise
Adverse Events
Encounter 12
Opening/Closing
Medications/ Side Effects
Diet
Mental Health
Adverse Events
Encounter 18
Opening/Closing
Medications/ Side Effects
Adverse Events
Final call summary
LPN Encounters with Module Topic
Encounter 1 (maps to Enc. 1
& 2 of RN/PharmD
schedule):
Opening/Closing
Medications
HTN knowledge*
Memory
Tobacco Use
Adverse Events
Encounter 5 (maps to Enc. 9 & 10
of RN/PharmD schedule):
Opening/Closing
Medications
Memory
HTN Knowledge*
Adverse Events
*HTN Knowledge is similar to the
RN/PharmD script for CVD
Knowledge
*Decision Making is similar to the
to the RN/PharmD script for
Patient-Physician Interaction
Encounter 2 (maps to Enc. 3
& 4 of RN/PharmD schedule
without goal follow up):
Opening/Closing
Medications
Social Support
Decision Making*
Adverse Events
Encounter 6 (maps to Enc. 11 &
12 of RN/PharmD schedule
without goal follow up):
Opening/Closing
Medications
Decision Making*
Adverse Events
Encounter 3 (maps to Enc. 5
& 6 of RN/PharmD schedule
without goal follow up):
Opening/Closing
Medications
Encounter 7 (maps to Enc. 13
&.14 of RN/PharmD schedule):
Opening/Closing
Medications
Alcohol
Contemp Clin Trials. Author manuscript; available in PMC 2017 September 01.
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
Jackson et al. Page 24
Stress
Adverse Events
Adverse Events
Encounter 4 (maps to Enc. 7
& 8 of RN/PharmD schedule
without goal follow up):
Opening/Closing
Medications
Alcohol
Tobacco Use
Adverse Events
Encounter 8 (maps to Enc. 15 &
16 of RN/PharmD schedule):
Opening/Closing
Medications
Adverse Events
Encounter 9 (maps to Enc. 17 &
18 of RN/PharmD schedule):
Opening/Closing
Medications/ Side Effects
Stress
Adverse Events
Enc. - encounter ; LPN – licensed practical nurse; PharmD - doctor of pharmacy (pharmacist); RN - registered nurse; HTN – hypertension, Pt – 
Patient, f/u – follow-up
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Table 6
Study Measures
Baseline 6
Month
12
Month
18
Month
Outcome
Blood pressure X X X X
Adverse Events
Adverse events* X X X
Falls, lightheadedness, fatigue X X X
Assessment of Cognitive Ability for Determination of Eligibility
Short Portable Mental Status Questionnaire (SPMSQ)52–54 X
Demographics and Socioeconomic Status
Gender X
Age X
Race X
Ethnicity X
Educational level (highest completed grade) X
Marital Status X X X X
Number of people living in the patient’s household X X X X
Adequacy of income X X X X
Employment status X X X X
Help with tasks X X X X
Components of Body Mass Index
Height X X X X
Weight X X X X
Additional Measures
Self-reported medication adherence – Modification of the Morisky
measure68
X X X X
Self-efficacy for management of hypertension69 X X X X
Exercise – Short International Physical Activity Questionnaire (IPAQ)70 X X X X
Literacy – Rapid Estimate of Adult Literacy in Medicine (REALM)71 X
Social support – Presence of a close personal relationship X
Quality of Life – EuroQol (EQ)-5D-5L72 X X X X
Organization of Primary Care – Patient Assessment of Chronic Illness
Care (PACIC)73–75
X X
Risk of having sleep apnea - Berlin questionnaire76 X
Health Behavior (smoking & alcohol use) X X X X
Health (years living with hypertension; home use of BP monitor;
diagnosis of sleep apnea and subsequent use of cpap machine)
X X X X
Family history of hypertension X
*Adverse events reported during study phone calls are also collected and reported.
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Table 7
Baseline Study Characteristics.
Overall
N = 385
TDM intervention
N = 192
Control
N = 193
Age, mean (SD) 63.5 (8.8) 64.2 (9.0) 62.9 (8.5)
Gender, observed
  Male 356 (92.5) 176 (91.7) 180 (93.3)
  Female 29 (7.5) 16 (8.3) 13 (6.7)
Marital statusd
  Married 219 (57.0) 115 (60.2) 104 (53.9)
  Living together, committed
relationship
6 (1.6) 2 (1.0) 4 (2.1)
  Divorced/separated 110 (28.6) 50 (26.2) 60 (31.1)
  Widowed 17 (4.4) 8 (4.2) 9 (4.7)
  Single, never married 32 (8.3) 16 (8.4) 16 (8.3)
Latino(a) or Hispanic
origin/descentd
  Yes 13 (3.4) 9 (4.8) 4 (2.1)
  No 366 (96.6) 179 (95.2) 187 (97.9)
Raced
  White 129 (33.8) 68 (35.6) 61 (31.9)
  Black 236 (61.8) 111 (58.1) 125 (65.4)
  Other 17 (4.5) 12 (6.3) 5 (2.6)
Highest level of education
  Less than high school graduate 27 (7.0) 14 (7.3) 13 (6.7)
  High school graduate or GED 108 (28.1) 60 (31.3) 48 (24.9)
  Some college or technical school 160 (41.6) 78 (40.6) 82 (42.5)
  College graduate 59 (15.3) 26 (13.5) 33 (17.1)
  Post college education 31 (8.1) 14 (7.3) 17 (8.8)
REALMd
  Less than 60 93 (24.5) 40 (21.3) 53 (27.7)
  60 or more 286 (75.5) 148 (78.7) 138 (72.3)
Household financial situationd
  After paying the bills, you still
have enough money for special
things that you want
142 (37.3) 74 (38.9) 68 (35.6)
  You have enough money to pay
the bills, but little spare money to
buy extra or special things
155 (40.7) 68 (35.8) 87 (45.5)
  You have money to pay the bills,
but only because you have to cut
back on things
47 (12.3) 27 (14.2) 20 (10.5)
  You are having difficulty paying 37 (9.7) 21 (11.1) 16 (8.4)
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Overall
N = 385
TDM intervention
N = 192
Control
N = 193
the bills, no matter what you do
Current living situation
  Own home/apartment 364 (94.5) 184 (95.8) 180 (93.3)
  No stable residence 21 (5.5) 8 (4.2) 13 (6.7)
Blood relative(s) with high blood
pressure
  Yes 305 (79.2) 150 (78.1) 155 (80.3)
  No 36 (9.4) 16 (8.3) 20 (10.4)
  Don’t know 44 (11.4) 26 (13.5) 18 (9.3)
Ever smoked or used tobacco
products
  Yes 283 (73.5) 142 (74.0) 141 (73.1)
  No 102 (26.5) 50 (26.0) 52 (26.9)
Smoked or used tobacco products
in past 6 monthsd
  Yes 108 (28.1) 49 (25.7) 59 (30.6)
  No 276 (71.9) 142 (74.3) 134 (69.4)
Current smokerd
  Yes 94 (24.5) 45 (23.6) 49 (25.4)
  No 290 (75.5) 146 (76.4) 144 (74.6)
Diabetes
  Yes 220 (57.1) 109 (56.8) 111 (57.5)
  No 165 (42.9) 83 (43.2) 82 (42.5)
Satisfied with BP controla,d, mean
(SD)
6.2 (2.8) 6.1 (2.7) 6.2 (2.8)
Average systolic BPb, mean (SD) 143.6 (17.6) 143.5 (17.7) 143.7 (17.5)
Average diastolic BPb, mean (SD) 79.9 (13.6) 79.4 (14.6) 80.3 (12.4)
Systolic BP statuse
  Significantly out of control 180 (46.8) 88 (45.8) 92 (47.7)
  Moderately out of control 115 (29.9) 57 (29.7) 58 (30.1)
  In control 90 (23.4) 47 (24.5) 43 (22.3)
Have someone to help with tasks, if
neededd
  Yes 337 (88.2) 163 (85.3) 174 (91.1)
  No 45 (11.8) 28 (14.7) 17 (8.9)
Medication adherence on modified
BP medication adherencec
  Non-adherent 164 (42.6) 82 (42.7) 82 (42.5)
  Adherent 221 (57.4) 110 (57.3) 111 (57.5)
Health professionals control my
healthd
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Overall
N = 385
TDM intervention
N = 192
Control
N = 193
  Strongly agree 66 (17.2) 37 (19.4) 29 (15.1)
  Agree 148 (38.6) 73 (38.2) 75 (39.1)
  Disagree 131 (34.2) 60 (31.4) 71 (37.0)
  Strongly disagree 38 (9.9) 21 (11.0) 17 (8.9)
SD = standard deviation, BP = blood pressure, REALM = Rapid Estimate of Adult Literacy in Medicine
Note. n (%) unless otherwise indicated.
aScale of 1–10, with 1 = definitely not satisfied and 10 = definitely satisfied
bAverage of three blood pressure measurements taken at baseline
cAssessed using Morisky self-reported adherence measure. A positive response to at least one question indicated non-adherence.
d
Missing data: note, unless otherwise indicated, responses of ‘don’t know’ or ‘refused’ were considered missing. Information is missing as follows: 
marital status-1, race-3, Latino(a)/Hispanic origin- 6, household finances-4, smoker, current and 6mo-1, satisfaction with blood pressure control-1, 
REALM-6, Help with tasks- 3, Health professionals control my health-2
eSignificantly out of control: systolic BP ≥ 140 for diabetics and ≥ 150 for those without diabetes; Moderately out of control: systolic BP ≥ 130 for 
diabetics and ≥ 140 for those without diabetes; In control: systolic BP < 130 for diabetics and < 140 for those without diabetes
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